InvestSMART

Memphasys Limited (ASX:MEM)

ALERT: Price-sensitive ASX Announcement for MEM
Current share price for MEM : $0.005 -0.002 (-25%)+
Announcement
Release
18 Sep 2026 8:45AM
Price at Release
$0.006
Full Release
download
Summary
Memphasys Limited (ASX: MEM) announced a three-year exclusive distribution agreement with INVIDO LAB s.r.o. for the Felix™ System across the Czech Republic, Slovakia and Kazakhstan, securing minimum contracted purchases of €416,200, or about A$674,000, over the initial term, with annual minimums rising from approximately A$139,000 in Year 1 to A$310,000 in Year 3. The agreement supports Memphasys’ strategy of expanding its installed base of Felix™ consoles and generating recurring revenue from single-use cartridges, while extending its European footprint into markets representing about 89,600 ART cycles, including 54,300 in the Czech Republic, 8,288 in Slovakia and 27,012 in Kazakhstan, where 7,000 publicly funded IVF/ICSI treatment quotas are available annually. INVIDO, an IVF and laboratory equipment supplier headquartered in Brno, will lead commercialisation and first-line support in the territories, backed by Memphasys’ strengthened European commercial capability following the appointment of Arne Schierau as Director, Commercial Operations Europe. The announcement positions the deal as part of Memphasys’ broader push to accelerate Felix™ adoption in Europe and build further international commercial relationships.
Key Points
  • Memphasys signed a three-year exclusive Felix™ distribution agreement with INVIDO LAB covering the Czech Republic, Slovakia and Kazakhstan.
  • The agreement secures minimum contracted purchases of €416,200, approximately A$674,000, over three years.
  • Annual minimum purchase commitments increase from €86,000 in Year 1 to €191,600 in Year 3, supporting a pathway to recurring revenue growth.
  • The contracted territories represent an addressable market of about 89,600 ART cycles across the Czech Republic, Slovakia and Kazakhstan.
  • Kazakhstan also supports 7,000 publicly funded IVF/ICSI treatment quotas annually, adding to market potential.
  • INVIDO is an established specialist IVF supplier with existing clinic relationships, local technical support and market presence across the territories.
  • Memphasys appointed Arne Schierau as Director, Commercial Operations Europe to strengthen on-the-ground European commercial execution.
  • The company said the agreement supports its strategy of expanding the Felix™ installed base and generating recurring cartridge revenue.
  • The distribution agreement includes exclusivity subject to minimum purchase and other commercial performance requirements.
  • Memphasys said it remains in advanced discussions with other potential commercial partners in priority international markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.